McDougle CJ, Goodman WK, Leckman JF et al. (1994), Haloperidol(Drug information on haloperidol) addition in fluvoxamine(Drug information on fluvoxamine)-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry 51(4):302-308.
McDougle CJ, Price LH, Goodman WK et al. (1991), A controlled trial of lithium(Drug information on lithium) augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy. J Clin Psychopharmacol 11(3):175-184 [see comment].
Mundo E, Guglielmo E, Bellodi L (1998), Effect of adjuvant pindolol(Drug information on pindolol) on the anti-obsessional response to fluvoxamine: a double-blind, placebo-controlled study. Int Clin Psychopharmacol 13(3):219-224.
Murray CJL, Lopez AD (1996), The Global Burden of Disease: a Comprehensive Assessment of Mortality and Morbidity from Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020. Cambridge, Mass.: Harvard University Press.
Owley T, Owley S, Leventhal B, Cook EH Jr (2002), Adderall augmentation of serotonin reuptake inhibitors in childhood-onset obsessive compulsive disorder. J Child Adolesc Psychopharmacol 12(2):165-171.
Pallanti S, Hollander E, Bienstock C et al. (2002a), Treatment non-response in OCD: methodological issues and operational definitions. Int J Neuropsychopharmacol 5(2):181-191.
Pallanti S, Quercioli L, Koran LM (2002b), Citalopram(Drug information on citalopram) intravenous infusion in resistant obsessive-compulsive disorder: an open trial. J Clin Psychiatry 63(9):796-801.
Pallanti S, Quercioli L, Paiva RS, Koran LM (1999), Citalopram for treatment-resistant obsessive-compulsive disorder. Eur Psychiatry 14(2):101-106.
